Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N3YT
|
|||
| Former ID |
DIB010296
|
|||
| Drug Name |
GLPG-0555
|
|||
| Synonyms |
Chondrocyte differentiation-modulating therapeutics (osteoarthritis), Galapagos/GlaxoSmithKline; GT-622 modulating compounds (osteoarthritis), Galapagos/GlaxoSmithKline
Click to Show/Hide
|
|||
| Indication | Osteoarthritis [ICD-11: FA00-FA05; ICD-9: 715] | Phase 1 | [1] | |
| Company |
Galapagos NV
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01278095) Oral Bioavailability of GLPG0555 in Different Solid Formulations. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.